Discussion
A global clinical trial testing SKY-0515, Skyhawk Therapeutics’ daily oral therapy for Huntington’s disease, will soon start recruiting adults with the genetic condition in the U.S., Canada, and the U.K. Regulatory authorities in all three countries have granted permission to open sites for the worldwide portion (004-WW,…